Loading...
On August 14, the U.S. FDA announced that it had approved the use of pretomanid under its limited population pathway for antibacterial and antifungal drugs. Approval is restricted to use in combination with bedaquiline and linezolid, solely for treatment of extensively drug-resistant (XDR) or treatment-intolerant/nonresponsive multidrug-resistant (TI/NRMDR) pulmonary tuberculosis. Pretomanid (previously known as PA-824) is a bicyclic nitroimidazole molecule with a dual mechanism of action: it blocks mycobacterial cell wall synthesis, and under anaerobic conditions it causes intracellular nitric oxide release, which leads to respiratory poisoning of mycobacterial cells (Science 2008; 322:1392 and FDA briefing document, June 6, 2019.
Pretomani…